MTOR and prostate cancer: Taken together, these findings support the rationale for combining pharmacological inhibition of the AR and PI3K-AKT-mTOR cascades to treat prostate cancer in the clinic, and highlight the need for further work to delineate the molecular mechanisms underpinning crosstalk between these two oncogenic cascades.